Anti-phosphatidylethanolamine (aPE) antibodies: A survey

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 185-193

  Mcintyre, John A ^a   Wagenknecht, Dawn R ^a  

^a St Francis Hospital & Health Centers   (United States)

Author keywords

Amnesia; Antiphospholipid antibodies; Antiphospholipid antibody syndrome; Kininogens; Platelet activation; Pregnancy loss; Stroke; Thrombin; Thrombosis

Indexed keywords

BINDING PROTEIN; BLOOD CLOTTING FACTOR 11; CARDIOLIPIN ANTIBODY; HIGH MOLECULAR WEIGHT KININOGEN; KININOGEN; LOW MOLECULAR WEIGHT KININOGEN; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PREKALLIKREIN; PROTHROMBIN;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TIME; CONFERENCE PAPER; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; THROMBOSIS; VASCULITIS;

EID: 0033835807     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0425     Document Type: Conference Paper

References (70)

1. The structural specificity of anti-phospholipid antibodies in autoimmune disease
2. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems
3. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies
4. Phospholipid in the hexagonal II phase is immunogenic: Evidence for immunorecognition of nonbilayer lipid phases in vivo
5. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification
6. Antiphospholipid antibody production during Mediterranean spotted fever
7. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin
8. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease
9. Detection of anti-phosphatidylethanolamine antibodies using flow cytometry
10. Association of lupus anticoagulant with antibody against phosphatidylserine
11. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity
12. Phospholipid binding proteins required for antiphospholipid antibody detection - An overview
13. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus
14. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis
15. Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies
16. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis
17. Childhood-onset systemic lupus erythematosus: Antiphospholipid antibodies in 37 patients and their first-degree relatives
18. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies
19. The effect of sera with antiphospholipid antibodies on endothelial cell procoagulant activity is dependent upon the charge of the phospholipids against which they are directed
20. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus
21. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases
22. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity
23. Prevalence and kininogen-dependence of antiphosphatidylethanolamine antibodies
24. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells
25. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance
26. Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: Their correlation with anticardiolipin antibodies and B2 glycoprotein-I plasma levels
27. Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma
28. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex
29. Phosphatidylethanolamine induces specific Conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies
30. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor
31. Development of the hemostatic system in the neonate and young infant
32. Evolution of blood coagulation activators and inhibitors in healthy human fetus
33. Some autoantibodies detected in the phosphatidylethanolamine ELISA recognize factor XI and/or prekallikrein
34. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies
35. High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation
36. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds
37. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA
38. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test
39. A sensitive assay for antiphosphatidylethanolamine antibody in patients with recurrent fetal loss
40. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss
41. Recurrent abortion and moderate or strong antiphospholipid antibody production
42. Patterns of anti-phospholipid antibody specificities
43. Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology
44. Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Colombian women with recurrent spontaneous abortions
45. Antiphospholipid antibody panels and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies
46. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome
47. Antibodies to B2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: Results of a prevalence study
48. Antiphospholipid antibodies associated with implantation failure after IVF/ET
49. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses
50. Criteria for antiphospholipid syndrome: Early pregnancy loss, fetal loss, or recurrent pregnancy loss?
51. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss
52. Antiphospholipid antibodies are a risk factor for early renal allograft failure
53. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients
54. Antiphospholipid antibodies in heart transplant recipients
55. The evolution, evaluation and interpretation of antiphospholipid antibody assays
56. Antiphospholipid antibodies are implicated in early renal allograft failure
57. Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies
58. The pre-conditioning incidence of antiphospholipid antibodies is not significantly increased in patients with bone marrow transplant-related organ dysfunction
59. Antiphospholipid antibodies are a risk factor for early renal allograft failure: Isolation of antiphospholipid antibodies from a thrombosed renal allograft
60. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation
61. Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin
62. Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients
63. Antiphospholipid antibodies in sickle cell disease
64. Antiphospholipid antibodies in alcoholic liver disease
65. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: A unifying 'membrane stress syndrome' hypothesis
66. Antibodies against phospholipids and oxidized LDL in alcoholic patients
67. Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus
68. Henoch-Schonlein Purpura and stroke: Antiphosphatidylethanolamine antibody (aPE) in CSF and serum
69. International consensus statement on preliminary classification criteria for define antiphospholipid syndrome: Report of an international workshop
70. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome